Remicade (infliximab) denied as experimental or investigational by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare Labels FDA-Approved Remicade "Experimental" — And Why That Label Usually Collapses on Appeal

When UnitedHealthcare denies Remicade (infliximab, HCPCS J1745) under an "experimental/investigational" rationale, the denial is almost always procedurally defective. Remicade has been FDA-approved since 1998 for RA, Crohn's, UC, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The actual driver is UHC's Commercial Medical Benefit Drug Policy for Infliximab products (eff. 02.01.2026), which designates Avsola (Q5121) and Inflectra (Q5103) as preferred and forces non-medical substitution to a biosimilar absent a documented exception. That is a non-preferred/step-therapy denial dressed up as "experimental" — and the distinction matters on appeal.

Procedural lever #1 — force the correct denial code. Under 29 CFR §2560.503-1(g)(1)(v)(B), UHC must identify the specific internal rule, guideline, or protocol relied upon. If the denial letter cites "experimental" but the underlying review actually applied the Infliximab Medical Benefit Drug Policy's biosimilar-preference criteria, that is a disclosure failure. Demand the full clinical rationale, the reviewing physician's specialty, and the version-dated policy document. Mis-categorization also matters because Pinto v. Aetna Life Ins. Co., 2014 WL 4651942 (D.N.M.), and the broader ERISA experimental-treatment line of cases place the burden on the plan administrator to substantiate an experimental classification with peer-reviewed evidence — a burden no carrier can meet against a 28-year-old FDA-approved biologic.

Procedural lever #2 — biosimilar interchangeability is not clinical equivalence. UHC's own policy carves out two exception pathways: (1) 14 weeks of Inflectra or Avsola with minimal clinical response, or (2) a physician attestation that clinical response would be expected to be superior with Remicade. The attestation pathway is underused. A prescriber letter citing antidrug antibody (ADA) formation risk on switch, prior immunogenicity data, or maintained remission on originator infliximab triggers the exception without requiring a forced failure trial. Cite the indication-specific data (e.g., AS patients with prior NSAID failure plus targeted immunomodulator history under the policy's AS criteria).

Procedural lever #3 — invoke step-therapy override rights. For ERISA-governed self-funded plans, 29 USC §1185d and state-law analogues (NY Ins. Law §4903, TX Ins. Code §1369.0546, CA H&S §1367.241) require expedited override when the preferred drug is contraindicated, expected to be ineffective, or the patient is stable on the requested drug. UHC's medical-benefit infliximab review is administered through Optum/Optum Specialty Pharmacy; route the appeal through the Optum medical-injectables PA fax channel listed on the denial, not Optum Rx (which handles pharmacy-benefit infusions only).

Tactical tip: Always request an ACA external review under 45 CFR §147.136 simultaneously with the second-level internal appeal — for experimental denials, external IRO reviewers (MCMC, MAXIMUS, MES) overturn at materially higher rates than UHC internal reviewers because the FDA-approval record is dispositive. Attach the FDA label, the specific BLA approval letter, and contemporaneous infusion records showing therapeutic response.